CAJ | 학술논문

目的：探讨用恩度联合化疗治疗恶性胸腹腔积液的临床效果。方法：对2011年1月～2013年10月期间我院收治的24例恶性胸腹腔积液患者的临床资料进行回顾性研究。对这24例患者使用恩度联合化疗药对其行腔内灌注治疗。治疗结束后，观察患者的疗效、生活质量改善的情况及其发生的毒性反应。结果：经过治疗，这些患者治疗的有效率为54.2%，其生活质量的改善率为66.7%。这些患者发生的毒性反应以1～2级为主，没有1例患者发生3～4级的毒性反应和与治疗有关的相关性死亡。结论：用恩度联合化疗药治疗恶性胸腹腔积液的疗效好，可使患者的生活质量得到很大的改善，而且其毒性反应患者可耐受。此治疗方法值得在临床上推广使用。
목적：탐토용은도연합화료치료악성흉복강적액적림상효과。방법：대2011년1월～2013년10월기간아원수치적24례악성흉복강적액환자적림상자료진행회고성연구。대저24례환자사용은도연합화료약대기행강내관주치료。치료결속후，관찰환자적료효、생활질량개선적정황급기발생적독성반응。결과：경과치료，저사환자치료적유효솔위54.2%，기생활질량적개선솔위66.7%。저사환자발생적독성반응이1～2급위주，몰유1례환자발생3～4급적독성반응화여치료유관적상관성사망。결론：용은도연합화료약치료악성흉복강적액적료효호，가사환자적생활질량득도흔대적개선，이차기독성반응환자가내수。차치료방법치득재림상상추엄사용。
Objective To observe the efficacy and safety of rh-endostatin injection(YH-16,endostar) combined with cytotoxic agents on malignant cavity effusion.Methods Twenty-four patients with malignant cavity effusion diagnosed at our hospital during January 2011 to April 2013 were analyzed retrospectively. The dosage was taken follow:endostar 45-60mg per time on d1、d4、d7;5-FU 0.75~1g orDDP 30~40mg each time on d1、d4、d7.The efficacy was evaluated strictly according to WHO criteria and safety according to NCI CTC AE 3.0 version criteria.Results The response rates was 54.2% (4 patients had CR,9 patients had PR). Among 24 responders,The improvement rate of QOL was 66.7%(16/24).The adverse reaction was mostly G1/2,No G3/4 toxicities occurred.No treat-ment-related death occurred.Conclusion Endostar combined with cytotoxic agents on malignant cavity effusion is effective and well tolerable ,and is worth of use and wide spread.